Harrow (HROW) Profit After Tax Growth (3y) (2013 - 2026)
Harrow (HROW) Profit After Tax Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 14.01% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 2.89% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 15.37% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Harrow | 1.53 Bn | 1.45 Bn | 50.36 Mn | -59.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -59.84% |
| Mar 31, 2026 | -60.77% |
| Dec 31, 2025 | 84.50% |
| Sep 30, 2025 | 29.22% |
| Jun 30, 2025 | 40.96% |
| Mar 31, 2025 | -93.92% |
| Dec 31, 2024 | 42.83% |
| Sep 30, 2024 | 20.28% |
| Jun 30, 2024 | -37.72% |
| Mar 31, 2024 | -301.06% |
| Dec 31, 2023 | -118.39% |
| Sep 30, 2023 | -35.89% |
| Jun 30, 2023 | -161.31% |
| Mar 31, 2023 | 19.89% |
| Dec 31, 2022 | -26.50% |
| Sep 30, 2022 | 17.78% |
| Jun 30, 2022 | -37.12% |
| Mar 31, 2022 | -30.35% |
| Dec 31, 2021 | -34.06% |
| Sep 30, 2021 | -49.07% |